Michael R. Migden, M.D., discusses locally advanced cutaneous squamous cell carcinoms. Background: Cemiplimab (REGN2810) produced substantial antitumor activity with durable…
Browsing: Head and Neck
Oropharyngeal Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip and Oral Cavity Cancer, Nasopharyngeal Cancer, Paranasai Sinus and Nasal Cavity Cancer, Salivary Gland Cancer, Squamous Cell Neck Cancer, Soft Tissue Sarcoma, Thyroid Cancer, News and Information
Michael R. Migden, M.D., discusses the phase 2 results of Cemiplimab. Background: Cemiplimab (REGN2810) produced substantial antitumor activity with durable…
Danny Rischin MD Of Peter MacCallum Cancer Centre Discusses Who Should Get Monotherapy Or Pembrolizumab Combo: Reasonable To Use Pembrolizumab…
Danny Rischin MD Of Peter MacCallum Cancer Centre Discusses KEYNOTE-48 Trial: 882 Patients Were Enrolled In Under 2 Years, Primary…
Danny Rischin MD Of Peter MacCallum Cancer Centre Discusses KEYNOTE-48 Trial Implications: Will Provide An Opportunity For Patients To Have…
David Anderson PhD Of VBI Vaccines Discusses VBI-1901 Vaccine: Two Different Components In The Vaccine gB & pp65 Delivered In…
David Anderson PhD Of VBI Vaccines Discusses Early Stages Of VBI-1901 Vaccine: Demonstrate Safety First, Encouraged By Correlations, Need To…
David Anderson PhD Of VBI Vaccines Discusses Are CMV antigens There: Multiple Publications Demonstrated Using A Variety Of Techniques That…
David M. Cognetti MD @KimmelCancerCtr Of Sidney Kimmel Cancer Center Discusses Photoimmunotherapy (PIT) Phase 2 Study Results: 30 Patients With…
David M. Cognetti MD @KimmelCancerCtr Of Sidney Kimmel Cancer Center Discusses Photoimmunotherapy (PIT) Phase 3 Study: Opening Now To Compare…
David M. Cognetti MD @KimmelCancerCtr Of Sidney Kimmel Cancer Center Discusses Photoimmunotherapy (PIT): Superior To Photodynamic Therapy Due To The…
David M. Cognetti MD @KimmelCancerCtr Of Sidney Kimmel Cancer Center Discusses Photoimmunotherapy Technology: Very Straight forward From A Technical Standpoint,…
GRACE – Global Resource for Advancing Cancer Education Published on Jul 29, 2016 5th video in our series ASCO 2016…
Byoung Chul Cho, M.D., Yonsei Cancer Center discusses Efficacy & Safety Of M7824. At ESMO Oncology Conference – Munich, Germany…
Byoung Chul Cho, M.D., Yonsei Cancer Center discusses NSCLC With M7824 Second Line Therapy. At ESMO Oncology Conference – Munich,…
Byoung Chul Cho, M.D., Yonsei Cancer Center discusses What To Expect In NSCLC & HN Cancer For 2019. At ESMO…
In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Susan Peterson,…
In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Susan Peterson,…
Drs Jared Weiss and Joshua Bauml discuss advances in treatment for head and neck cancer from ASCO 2018.
Drs Jared Weiss and Joshua Bauml discuss advances in treatment for head and neck cancer from ASCO 2018.
Drs Jared Weiss and Joshua Bauml discuss advances in treatment for head and neck cancer from ASCO 2018.
Locally advanced head and neck cancer is treated with chemotherapy and radiation as standard, with an aim to cure the…
Cetuximab monotherapy is the standard of care for platinum-resistant non-HPV related metastatic head and neck cancer; however, response and survival…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Ezra Cohen, MD, FRCPC, FASCO, of…
Metastatic head and neck cancer that has progressed following platinum therapy generally has a very poor prognosis. In this video,…
Prognoses for patients with relapsed metastatic head and neck cancer that has progressed on prior platinum therapy are poor. Here,…
Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, presented…